AI 在生物制药研发中的角色：机遇、必然还是双重驱动？.pptxVIP

Smartbet,

onlyoption,

orboth?

BiopharmaRD

turnstoAI.

Makeitreal.

Tableofcontents

49

Insightsfroma

seniorbiopharmaleaderataglobalpharmaceuticalcompany

04

Executivesummary

AIisthebiopharmaindustry’s

prescriptionforailinginnovation

HowAIisreshapingpartsoftheRD

valuechaintoday

Layingthe

groundworkforbigbetsonAIinRD

30

22

10

Smartbet,onlyoption,orboth?BiopharmaRDturnstoAI.

CapgeminiResearchInstitute2026

2

67

ReseaΓchmethodology

Howbiopharmaorganizationscanaccelerateand

scaleAIinRD

66

Conclusion

Barriersto

biopharmarealizingAI’spotential

58

50

Smartbet,onlyoption,orboth?BiopharmaRDturnstoAI.

CapgeminiResearchInstitute2026

3

Convergingtechnologyincludingadvancesinbiology,physics,andcomputationalpowerareunlockingthisbreakthroughnow.

Ourglobalresearchrevealsthatbiopharma

organizationsrecognizethispotential.Itfindsthat82%ofexecutivesbelieveAIwillfundamentally

transformbiopharmaRD,and60%agreethatcompaniesfailingtoscaleAIwillfallbehindin

innovationandmarketrelevance.ExecutivesalsoseeAIasakeyenablerinearly-stageRD,wherethemostcomplexchallengesreside,supportingthedesignofexperimentalapproachesand

refiningmodelsandprototypes.Infact,63%anticipatethatmostnewmolecularentities

(NMEs)willoriginatefromAI-drivenplatformswithinthenextdecade.

Thepharmaceuticalandbiotechnology

(biopharma)industryfacespersistent,long-standingchallengestoitsRDefficiency.

Topamongthemarethehighcostofdrug

developmentandelevatedclinicalfailurerates.ThereturnonRDinvestmentshasundergoneasteadydeclinetoanowflat,butunacceptablelevel,makingitincreasinglydifficulttobring

successfulnewdrugstomarket.

AIisnowemergingasapowerfulcatalystfor

breakthroughsinRD,preciselyintheareas

wheretheindustryhasstruggledmostinrecentyears.By